Opinion statement There are currently no disease-modifying treatments for progressive
supranuclear palsy (PSP) or corticobasal degeneration (CBD), and no approved …

Objective An inversion polymorphism of approximately 900kb on chromosome 17q21, which
includes the microtubule‐associated protein tau (MAPT) gene defines two haplotype clades …

Progressive supranuclear palsy (PSP) is a clinicopathological entity typically presenting as
an akinetic rigid syndrome with early falls, axial rigidity, vertical supranuclear gaze palsy and …

Primary tauopathies are a group of neurodegenerative diseases in which tau is believed to
be the major contributing factor of the neurodegenerative process. In primary tauopathies …

Tau and amyloid precursor protein (APP) are key proteins in the pathogenesis of sporadic
and inherited Alzheimer's disease. Thus, developing ways to inhibit production of these …

Tau is a microtubule-associated protein involved in microtubule assembly and stabilization.
Abnormal filamentous tau deposits constitute a major defining characteristic of several …

An unusually high frequency of atypical Parkinson syndrome has been delineated over the
last 5 years in the French West Indies. Postural instability with early falls, prominent frontal …

A primary haplotype (H1) of the microtubule‐associated protein Tau (MAPT) gene is
associated with Parkinson's disease (PD). However, the mechanism for disease …

The MAPT H1 haplotype has been associated with four-repeat (4R) tauopathies, including
progressive supranuclear palsy, corticobasal degeneration, and argyrophilic grain disease …

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), previously
described as Parkinsonian syndromes are also cognitive disorders, and biologically related …